Atazanavir-d5

Atazanavir-d5

• CAS Number: 1132747-14-8
• UNSPSC Description: Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
• Target Antigen: Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; Isotope-Labeled Compounds; P-glycoprotein; SARS-CoV
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Others
• Field of Research: Infection; Cancer
• Solubility: 10 mM in DMSO
• Smiles: [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1C[C@H](NC([C@H](C(C)(C)C)NC(OC)=O)=O)[C@@H](O)CN(NC([C@H](C(C)(C)C)NC(OC)=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2
• Molecular Weight: 709.89
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.|[3]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported